Clinical Trial News Archive - November 2022
November 1, 2022
- Cycle Pharmaceuticals to launch Tascenso ODT® (fingolimod) in US in Q1 2023
- Teon Therapeutics Announces First Patient Treated in Phase 1/2 Clinical Trial of TT-816, a Novel Oral Immune Checkpoint Inhibitor, in Patients with Advanced Solid Tumors
- Dragonfly Therapeutics Announces First Patient Dosed in Clinical Trial Evaluating Solid Tumor Targeting TriNKET Conducted by Merck
- NIH-Funded Study Shows Blood Pressure Levels Rose During Pandemic
- NIH Study in Mice Provides Insight Into How Brain Activity is Fine-Tuned
- Pfizer Announces Positive Top-Line Data of Phase 3 Global Maternal Immunization Trial for its Bivalent Respiratory Syncytial Virus (RSV) Vaccine Candidate
- Actinium Announces Positive Top-line Results from Pivotal Phase 3 SIERRA Trial of Iomab-B in Patients with Active Relapsed or Refractory Acute Myeloid Leukemia
- Vigil Neuroscience Receives FDA Fast Track Designation for VGL101 for the Treatment of Patients with ALSP
November 2, 2022
- NIH-Funded Study Finds Personalized Kidney Screening for People with Type 1 Diabetes Could Reduce Costs, Detect Disease Earlier
- GSK’s Respiratory Syncytial Virus Older Adult Vaccine Candidate Granted Priority Review by US FDA
- Brexogen's Exosome Therapy for Atopic Dermatitis, 'BRE-AD01' Accepted for Phase 1 Clinical Trials by US FDA
November 3, 2022
- Pfizer’s Elranatamab Granted FDA Breakthrough Therapy Designation for Relapsed or Refractory Multiple Myeloma
- Abeona Therapeutics Announces Positive Topline Results with Both Co-Primary Endpoints Met in Pivotal Phase 3 VIITAL™ Study of EB-101
- EAGLE-2 and EAGLE-3 Phase III Trials for Gepotidacin Stopped Early for Efficacy Following Pre-Planned Interim Analysis by Independent Data Monitoring Committee
November 4, 2022
- EMPA-KIDNEY trial showed significant benefit of Jardiance in reducing kidney disease progression or cardiovascular death in people with chronic kidney disease
- Pfizer and BioNTech Announce Updated Clinical Data for Omicron BA.4/BA.5-Adapted Bivalent Booster Demonstrating Substantially Higher Immune Response in Adults Compared to the Original COVID-19 Vaccine
November 7, 2022
- Geneos Therapeutics Announces Positive Clinical Data for Personalized Therapeutic Cancer Vaccines in Ongoing Liver Cancer Trial
- CinCor Pharma Announces Late-Breaking Presentation of Phase 2 BrigHtn Data on Baxdrostat in Treatment-Resistant Hypertension at the 2022 American Heart Association Scientific Sessions
- Pivotal Phase 3 Efficacy and Safety Data for Ferring’s RBX2660 Published in Drugs
- AbbVie Announces Late-Breaking Results from Phase 2 Exploratory NOVA Trial of Novel Investigational Neurotoxin AGN-151607 for the Prevention of Postoperative Atrial Fibrillation in Cardiac Surgery Patients
- Late-Breaking Data from Pivotal Phase 3 PRECISION Study Demonstrates Significant and Sustained Effect of Aprocitentan on Lowering Blood Pressure for Patients with Difficult-to-Control Hypertension
November 8, 2022
- Novavax Phase 3 COVID-19 Omicron Trial Supports the Continued and Future Use of Novavax Prototype Vaccine as a Booster
- Ionis announces positive data from GSK's Phase 2b clinical study of bepirovirsen
November 9, 2022
- PT027 Recommended by FDA Advisory Committee as New Rescue Treatment for Asthma
- Resolve Therapeutics Completes Enrollment of Phase 2 Long Covid Clinical Trial
November 10, 2022
- Rigel Announces Publication of Early Clinical Data of Olutasidenib in The Lancet Haematology
- Experimental Cancer Vaccine Shows Promise in Animal Studies
- NIH-Funded Researchers to Begin Study of Intravenous Iron Treatment for Post-Pregnancy Anemia
- Kineret Authorized for Emergency Use by FDA for the Treatment of COVID-19 Related Pneumonia
November 11, 2022
- QUE Oncology's non-hormonal therapy reduces hot flushes and night sweats in women with breast cancer
November 13, 2022
November 14, 2022
- Roche Provides Update on Phase III GRADUATE Programme Evaluating Gantenerumab in Early Alzheimer’s Disease
- Moderna's BA.4/BA.5 Targeting Bivalent Booster, mRNA-1273.222, Meets Primary Endpoint of Superiority Against Omicron Variants Compared to Booster Dose of mRNA-1273 in Phase 2/3 Clinical Trial
- Aria Pharmaceuticals Presents Positive In Vivo Data on Lead Idiopathic Pulmonary Fibrosis Treatment Candidate
- GSK Announces Positive Phase IIa Study Results for a New First-in-Class Candidate Medicine for Patients with Tuberculosis
November 15, 2022
- OncoSec presents encouraging early data with TAVO-EP combined with Opdivo in neoadjuvant melanoma
- CANbridge Pharmaceuticals Announces Orphan Drug Designation Granted to CAN 106 for the Treatment of Myasthenia Gravis
November 16, 2022
- NIH Researchers Unlock Pattern of Gene Activity for ADHD
- CellVax Selects Theragent as Manufacturing Partner for Phase 2 Clinical Trial for Prostate Cancer Immunotherapy
November 17, 2022
- INOVIO Provides an Update on Lassa Fever and MERS Programs
- Astellas Announces Zolbetuximab Meets Primary Endpoint in Phase 3 SPOTLIGHT Trial as First-Line Treatment in Claudin 18.2 Positive, HER2-Negative Locally Advanced or Metastatic Gastric and Gastroesophageal Junction (GEJ) Cancers
- Northwest Biotherapeutics Reports Positive Top-Line Results From Phase 3 Trial of DCVax-L for Glioblastoma
- MAPS PBC Completes Second Phase 3 "MAPP2" Trial of MDMA-Assisted Therapy for Treatment of PTSD
November 18, 2022
- Pfizer and BioNTech Report New Data on Omicron BA.4/BA.5-Adapted Bivalent Booster Demonstrating Improved Immune Response Against Emerging Omicron Sublineages
- Cleveland Researchers Discover New Oral Drug for Lowering Cholesterol
November 21, 2022
November 22, 2022
- Palisade Bio is Granted Fast Track Designation from the U.S. Food and Drug Administration for LB1148 for Accelerated Return of Bowel Function following GI Surgery
- TC BioPharm Begins Dosing Phase 2B Clinical Study Evaluating its Lead Compound, OmnImmune, in Patients with Acute Myeloid Leukemia
November 23, 2022
November 24, 2022
November 27, 2022
November 28, 2022
- Gilead and Arcus Biosciences Announce Positive Update on Joint TIGIT Program From Interim Analysis of ARC-7 Study in Non-Small Cell Lung Cancer
- Genentech Provides Update on Tecentriq U.S. Indication for Previously Untreated Metastatic Bladder Cancer
- US Partial Clinical Hold on Diamyd Phase III Trial Lifted by the FDA
November 29, 2022
- Eisai Presents Full Results of Lecanemab Phase 3 Confirmatory Clarity Ad Study for Early Alzheimer’s Disease At Clinical Trials On Alzheimer’s Disease (Ctad) Conference
- Mebias Discovery Initiates a Phase I Clinical Trial of MEB-1170, a Novel Analgesic Drug Candidate for the Treatment of Pain and Prevention of Opioid Use Disorder
- WHO Updates Emergency Use Listing for Novavax Nuvaxovid COVID-19 Vaccine as a Primary Series in Adolescents and as a Booster in Adults
November 30, 2022
- Lilly Shares Positive Donanemab Data in First Active Comparator Study in Early Symptomatic Alzheimer's Disease
- FDA Announces Bebtelovimab is Not Currently Authorized in Any US Region
- Nimbus Therapeutics Announces Positive Topline Results for Phase 2b Clinical Trial of Allosteric TYK2 Inhibitor in Psoriasis
- Innoviva Announces FDA Acceptance and Priority Review of New Drug Application for Sulbactam-Durlobactam (SUL-DUR)
- Full results of lecanemab Phase 3 confirmatory Clarity AD study for early Alzheimer's disease published in the NEJM
- Green-Tinted Eyeglasses May Reduce The Need For Opioids To Manage Severe Pain
- Acoziborole: Investigational Single-Dose Oral Treatment Raises Hope for Elimination of Sleeping Sickness in Africa
- Xspray Pharma’s Drug Candidate XS004 Granted Orphan Drug Designation in the US for the Treatment of Acute Lymphoblastic Leukemia
Clinical trial results archive
- 2024
- January, February, March, April, May
- 2023
- January, February, March, April, May, June, July, August, September, October, November, December
- 2022
- January, February, March, April, May, June, July, August, September, October, November, December
- 2021
- January, February, March, April, May, June, July, August, September, October, November, December
- 2020
- January, February, March, April, May, June, July, August, September, October, November, December
- 2019
- January, February, March, April, May, June, July, August, September, October, November, December
- 2018
- January, February, March, April, May, June, July, August, September, October, November, December
- 2017
- May, June, July, August, September, October, November, December
- 2016
- October
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.